Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
Synopsis
The vaccine was approved for initial immunization in individuals aged six years or older and as a booster immunization in those aged 12 years or older in the country.
Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda.
The vaccine was approved for initial immunization (first and second vaccinations) in individuals aged six years or older, and as a booster immunization (following the third vaccination) in individuals aged 12 years or older in the country.
Under Novavax’s deal with Takeda, the company is also eligible to receive royalties on net sales of Nuvaxovid from Takeda in this vaccination season.
Get updates to this developing story <directly on Stocktwits<.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.